$MSPR

MSP Recovery, Inc. (MSPR): Entry into a Material Definitive Agreement

MSP Recovery, Inc. (MSPR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001802450 0001802450 2026-08-04 2026-08-04 0001802450 MSPR:ClassCommonStock0.0001ParValuePerShareMember 2026-08-04 2026-08-04 0001802450 MSPR:RedeemableWarrantsEachLotOf4375WarrantsExercisableForOneShareOfClassCommonStockAtExercisePriceOf50312.50PerShareMember 2026-08-04 2

Original reporting
Published Aug 14, 2026, 9:13 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 9:16 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$MSPR
Neutral
medium confidence
Mentioned
$MSPR
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MSPRNeutralLow
01

Why it matters

The 8-K adds two small one-time Hazel advances and two VRM recovery-proceeds advances, but it reiterates there is no ongoing funding obligation and no reinstatement of prior availability.

02

Market read

This is a liquidity-related disclosure for an OTC issuer, but the amounts are small and the agreements do not create committed future funding.

03

What to watch

Traders may overreact to the headline liquidity amount; the key is that the facility remains non-committed and future advances are not reasonably expected.

Relevance 6/10Novelty 5/10Timing: after-hours filing on Aug. 14, 2026 for Aug. 4 and Aug. 13/12 funded advances

Background

MSP Recovery is party to a working capital credit facility with Hazel that uses a discretionary Operational Collection Floor, with no committed liquidity or borrowing base.

Company-level read

Ticker impact

$MSPRNeutralMedium confidence
Context

MSP Recovery entered letter agreements with Hazel and VRM for two one-time advances totaling $0.11 million to fund operating expenses and payroll/IT.

Expected impact

Likely modest, short-lived relief reaction; downside risk remains if the company cannot secure further discretionary funding.

Evidence & confidence

The 8-K emphasizes the advances are standalone, do not reinstate the Operational Collection Floor, and Hazel has no obligation for future funding.

Market effects

Highlights discretionary working-capital structures and reliance on lender discretion for small-cap OTC issuers.

None evident from the filing.

None evident from the filing.

Counterpoint

The incremental cash may be a stopgap, and the explicit statement that no further funding is available can reinforce balance-sheet risk rather than reduce it.

Key entities

  • MSP Recovery, Inc.

    OTC-listed company filing an 8-K for entry into material definitive agreements providing one-time advances.

  • Hazel Partners Holdings LLC

    Administrative agent and lender under the company’s working capital credit facility; provides discretionary one-time advances.

  • VRM MSP Recovery Partners, LLC

    Provides one-time advances of recovery proceeds for payroll and certain IT expenses.

Related articles

$TSNMed

Tyson Foods beef plant closures ‘devastating’ for communities | Arkansas Democrat Gazette

Tyson Foods said it will close two beef processing plants in Joslin, Illinois and Eagle Mountain, Utah, and is exploring selling its Pasco, Washington facility, citing tight cattle supply and a plan to optimize its beef network. Beef groups and officials cited impacts on producers and about 2,500 workers. Tyson expects 2026 fiscal-year beef operating losses of $500 million to $650 million; shares rose to $58.17.

$ATNMMed

Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update

Actinium Pharmaceuticals (NYSE American: ATNM) said it expanded Actimab-A intellectual property with multiple newly issued US patents and additional pre-grant/allowed applications, covering uses in AML, MDS, and solid tumors, including combinations with venetoclax and CLAG-M. The company also amended its IND to add a manufacturing source and reported NYSE American listing compliance plan acceptance through Nov. 27, 2027.

$GOOGMed

Alphabet Just Borrowed $25 Billion, and $2.5 Billion of It Isn't Due Until 2066

Alphabet (GOOG, GOOGL) closed a $25 billion senior notes sale with 10 tranches maturing from 2028 to 2066, including $2.5 billion at 6.5% due Aug 2066. Alphabet said proceeds will go to general corporate purposes, possibly debt repayment. The company raised capex guidance to $195-$205 billion for 2026, pushing long-term debt to about $123 billion by June 30.

$TSNMed

Tyson to sell WA beef plant, close facilities in Illinois, Utah

Tyson Foods said it will seek a buyer for its Pasco, Washington beef plant and close its meat processing facilities in Joslin, Illinois and Eagle Mountain, Utah, citing a cattle shortage. Tyson will consolidate beef packing at plants in Nebraska, Kansas and Texas and add a second shift in Amarillo, Texas. The Justice Department is probing antitrust activity involving Tyson, JBS, Cargill and National Beef.

$SLNMedAI 8/10

Silence Therapeutics plc: Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs

Silence Therapeutics plc (Nasdaq: SLN) said it closed an upsized underwritten public offering of 14,907,407 ADSs at $13.50 per ADS, with underwriters fully exercising their option for 1,944,444 additional ADSs. Gross proceeds were about $201.3 million before fees. Jefferies, Morgan Stanley, Cantor and William Blair managed the deal.